EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells

Yujia Zhou, Hejing Liu, Shuangjia Pan, Luyi Ruan, Jiayi Ruan, Jiaru Chen, Huihui Ji, Xueqiong Zhu iD

The FASEB Journal · 2026

DOI: 10.1096/fj.202504556rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Yujia Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of W…. Hauptthemen laut MEDLINE: Cisplatin, Caveolin 1, Simvastatin, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Natural Science Foundation of Zhejiang Province, Zhejiang Key Laboratory of Traditional Chinese Medicine for Diagnosis and Treatment of Gynecological Cancers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential beyond their lipid‐lowering effects. Statin utilization is found to be significantly linked to decreased cervical cancer incidence and mortality. However, whether statins affect chemosensitivity to cisplatin in cisplatin‐resistant cervical cancer remains to be clarified. In cervical cancer cisplatin‐resistant cell lines (SiHa‐DDP and C33a‐DDP) constructed from their parental cells, the effects of seven statins (simvastatin, fluvastatin, pitavastatin, lovastatin, atorvastatin, rosuvastatin, and pravastatin) on cell viability in cisplatin‐resistant cells and corresponding parental cells were assessed using the CCK‐8 assay. Compared with parental counterparts, the IC 50 values of seven statin drugs were markedly elevated in cells exhibiting cisplatin resistance. Simvastatin significantly enhanced the efficacy of cisplatin in cisplatin‐resistant cervical cancer cells, demonstrating a synergistic anti‐cancer effect (CI < 1). Combined therapy using simvastatin and cisplatin inhibited cell viability and migration while promoting cell apoptosis. Mechanistically, simvastatin downregulated protein expressions of caveolin‐1 (CAV1), PI3K, and p‐AKT. CAV1 knockdown in SiHa‐DDP and C33a‐DDP cells markedly increased cisplatin sensitivity, confirming its critical role in chemoresistance. Rescue experiments showed that CAV1 overexpression partially counteracted the inhibitory effects of simvastatin. In vivo, compared with monotherapies, simvastatin combined with cisplatin treatment markedly suppressed tumor growth, reduced CAV1 protein expression, decreased the percentage of Ki67‐positive cells and promoted apoptosis. In all, simvastatin enhanced cisplatin sensitivity by suppressing the CAV1‐mediated PI3K/AKT pathway involvement in the development of cisplatin resistance in cervical cancer cells. These findings reveal a novel mechanism in cervical cancer cells resistant to cisplatin by which simvastatin may serve as a potential adjuvant to improve the therapeutic efficacy of cisplatin‐based chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinCaveolin 1SimvastatinUterine Cervical NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesHumansFemaleSignal TransductionAnimalsCell Line, TumorMice, NudeAntineoplastic AgentsMiceApoptosisCell ProliferationHydroxymethylglutaryl-CoA Reductase InhibitorsMice, Inbred BALB C

Stichwörter der Autor:innen

Caveolin‐1PI3K/AKT signaling pathwaycervical cancercisplatin resistancesimvastatin

Substanzen

CisplatinCaveolin 1SimvastatinProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAntineoplastic AgentsCAV1 protein, humanHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
  • Alberta Institute, Wenzhou Medical University, Wenzhou, People's Republic of China.

ORCID-Profile: Xueqiong Zhu

Förderung

  • the Natural Science Foundation of Zhejiang Province
  • Zhejiang Key Laboratory of Traditional Chinese Medicine for Diagnosis and Treatment of Gynecological Cancers

Zitieren

APA

Zhou, Y., Liu, H., Pan, S., Ruan, L., Ruan, J., Chen, J., Ji, H., & Zhu, X. (2026). Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells. The FASEB Journal. https://doi.org/10.1096/fj.202504556rr

Vancouver

Zhou Y, Liu H, Pan S, Ruan L, Ruan J, Chen J, et al. Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells. The FASEB Journal. 2026. doi:10.1096/fj.202504556rr

BibTeX
@article{Zhou2026,
  author = {Zhou, Yujia and Liu, Hejing and Pan, Shuangjia and Ruan, Luyi and Ruan, Jiayi and Chen, Jiaru and Ji, Huihui and Zhu, Xueqiong},
  title = {Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells},
  journal = {The FASEB Journal},
  year = {2026},
  doi = {10.1096/fj.202504556rr}
}
Kostenlos starten →